Latest News & Features
Americas
The system governing preliminary injunctions for pharmaceutical patent infringement should be revised to
stave off potential frivolous cases, say Hedwig Lindner and Manuel Morante. 1 May 2012
Big Pharma
Russia’s life sciences industry is growing rapidly, say Vadim Chagin and Maria Nilova. 1 May 2012
article
LSIPR talks to Matt McBride about how Science IP can help businesses ensure their patent plans get off to the best possible start. 1 May 2012
Big Pharma
Advocate-General Verica Trstenjak has delivered an opinion in the case of Neurim Pharmaceuticals that, if followed by the Court of Justice of the EU, will profoundly liberalise the law governing SPCs in Europe. 1 January 2012
Biotechnology
The Supreme Court’s much-anticipated Prometheus decision has prompted strong reactions among IP practitioners, as MaryAnne Armstrong, PhD, explains. 1 January 2012
Big Pharma
When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne. 1 January 2012
Biotechnology
The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important. 1 January 2012
Biotechnology
The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes. 1 January 2012
Biotechnology
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of
IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs. 1 January 2012
Americas
There is a perfect storm brewing in the healthcare industry. Over the past few years, there has been an unprecedented rise in the trade of illicit healthcare products in the secondary market. 1 May 2011